Bayer Aktie: Shares Surge to 12-Month High Amid Technical Rally
LEVERKUSEN, Germany — 17 February 2026 – The Bayer AG (BAYN) share price has demonstrated significant upward momentum during Tuesday’s trading session, reaching its highest valuation in over a year. Despite lingering skepticism from institutional analysts regarding long-term structural challenges, the stock is currently riding a wave of technical optimism and positive sentiment ahead of the upcoming financial reporting cycle.
Current Market Performance and Real-Time Data
As of midday on 17 February 2026, the Bayer share (ISIN: DE000BAY0017) is trading at approximately €46.82 on the XETRA exchange, marking a daily increase of roughly 1.50%. This follows a period of sustained growth since the beginning of the year, with the stock gaining over 22% year-to-date.
Key Financial Indicators (17 February 2026)
- Current Price: €46.82 (XETRA, 11:49 CET)
- Daily Change: +1.50%
- 52-Week High: Reached today, 17 February 2026
- Market Sector: Pharmaceuticals and Agriculture (Life Sciences)
Historical Context and Revenue Trends
Bayer’s financial trajectory over the past few years has been marked by volatility, primarily driven by legal complexities in the US crop science division and a strategic shift in its pharmaceutical pipeline. The following table outlines the group’s performance leading into the current fiscal period.
| Fiscal Year | Revenue (Million €) | EBITDA (Million €) | Dividend per Share (€) |
|---|---|---|---|
| 2024 | 46,606 | (Data Pending) | 0.11 |
| 2023 | 47,637 | 11,701 | 0.11 |
| 2022 | 50,739 | 13,513 | 2.40 |
| 2021 | 44,081 | 11,178 | 2.00 |
Analyst Sentiment and Future Outlook
The investment community remains divided on the “Bayer Aktie.” While the stock is currently “eiling from high to high” in technical terms, fundamental valuations vary significantly between major financial institutions.
The UBS Neutral Stance
The Swiss major bank UBS recently maintained its “Neutral” rating for Bayer. Despite the recent rally, UBS analysts have set a price target of €32.00, suggesting that the current market price may be overextended relative to the company’s underlying earnings potential and the risks associated with its agricultural division.
Bullish Momentum and Targets Over €50
Conversely, other market analysts point to a “technical miracle,” citing strong momentum that could push the share price above the €50.00 threshold. This optimism is fueled by expectations of robust fourth-quarter results from 2025 and a potential stabilization in the company’s legal environment.
Dividend Policy for 2026
Following the drastic reduction of the dividend to the legal minimum of €0.11 per share for the fiscal years 2023 and 2024, investors are closely watching the upcoming Annual General Meeting (AGM). Historically, Bayer pays its dividend once a year in April. For the 2024 fiscal year, the dividend of €0.11 was approved at the AGM on 25 April 2025 with a 99.32% majority.
Frequently Asked Questions (FAQ)
When is the next Bayer Annual General Meeting?
The Annual General Meeting for the 2025 fiscal year is expected to take place in April 2026. Official confirmation of the date is typically provided in the company’s financial calendar published on the Bayer Global Investor Relations portal.
What is the current dividend yield for Bayer?
Based on the last paid dividend of €0.11 and the current share price of approximately €46.82 (as of 17 February 2026), the dividend yield is approximately 0.23%. This reflects the company’s current strategy of debt reduction over high shareholder payouts.
Why is the Bayer share price rising today?
The rise on 17 February 2026 is attributed to a broader technical recovery in the German chemical and pharma sectors, as well as positive sentiment ahead of the upcoming 2025 annual report, which is expected to provide deeper insights into the company’s restructuring progress.
Is Bayer a good buy in 2026?
Investment opinions are split. While technical analysts see a strong upward trend with targets above €50, fundamental analysts like those at UBS remain cautious with targets as low as €32, citing long-term structural risks.